Skip to main content
. 2023 Oct 3;13:1249106. doi: 10.3389/fonc.2023.1249106

Table 3.

Clinical response to 2nd-line therapy.

Osimertinib
N =58 (%)
Nonosimertinib
N = 44 (%)
P value
CR 0 0 0.001
PR 30 (51.7%) 10 (22.7%)
SD 26 (44.8) 24 (54.5%)
PD 2 (3.5%) 10 (22.7%)
RR (%) 51.7 22.7
DCR (%) 96.5 77.3

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; RR, response rate; DCR, disease control rate.